Company
X4 Pharma
Driving progress for people living with rare immune disorders
Also known as X4 Pharmaceuticals, X4 Pharmaceuticals, Inc.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Headquarters
- Boston, Massachusetts, United States
- Legal name
- X4 Pharmaceuticals, Inc.
- x4pharma.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
With Rare Resolve, X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. We have successfully developed mavorixafor, receiving U.S. approval for XOLREMDI® (mavorixafor) in its first indication.
Funding snapshot
- Total raised
- $320MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $85M2025-08-13
Funding rounds
- Round, 2025
- $85M2025-08-13, SEC form D sold, 18 investors
- Round, 2023
- $65M2023-05-18, SEC form D sold, 22 investors
- Round, 2022
- $55.7M2022-07-06, SEC form D sold, 23 investors
- Round, 2017
- $20M2017-11-20, SEC form D sold, 1 investor
- Round, 2017
- $45.5M2017-04-24, SEC form D sold, 18 investors
- Round, 2016
- $15M2016-04-12, SEC form D sold, 10 investors
- Round, 2015
- $4M2015-12-16, SEC form D sold, 8 investors
- Round, 2013
- $20M2013-07-30, SEC form D sold, 8 investors
- Round, 2011
- $9.6M2011-01-31, SEC form D sold, 7 investors
- Round, 2010
- $400K2010-09-15, SEC form D sold, 7 investors
Products
- Web
- XOLREMDI
- Other
- XOLREMDI (mavorixafor)
Loading relationship preview